Table 2.
All-cause mortality
|
CVD mortality
|
CVD hospitalizations or CVD mortality
|
||||
---|---|---|---|---|---|---|
No. of studies | RR (95% CI) | No. of studies | RR (95% CI) | No. of studies | RR (95% CI) | |
All studies | 10 | 1.19 (0.88–1.62) | 6 | 1.29 (0.73–2.27) | 7 | 1.43 (1.10–1.85) |
Studies that controlled for important confounding factors* | 6 | 1.36 (0.93–2.04) | 5 | 1.63 (1.11–2.39) | 6 | 1.55 (1.28–1.87) |
Studies that controlled for important confounding factors† | 4 | 1.34 (0.73–2.47) | 3 | 1.72 (0.93–3.20) | 4 | 1.50 (1.25–1.78) |
Studies that did not control for duration of diabetes excluded. For all-cause mortality, excluding the studies by Gulliford (12), Johnson (14), and Fisman (21). For CVD mortality and the composite end point of CVD hospitalizations or CVD mortality, excluding the study by Johnson (23).
Studies that did not control of duration of diabetes or previous CVD excluded. For all-cause mortality, excluding the studies by Gulliford (12), Johnson (14), Olsson (16), Bruno (20), and Fisman (21). For CVD mortality and the composite end point of CVD hospitalizations or CVD mortality, excluding the studies by Olsson (16), Johnson (23), and Bruno (20).